Imperial Prostate 9 - ATLAS (Approaches To Long-Term Active Surveillance)

Launched by IMPERIAL COLLEGE LONDON · Feb 19, 2024

Keywords

ClinConnect Summary

The Imperial Prostate 9 - ATLAS trial is studying how effective regular MRI scans are in detecting changes in prostate cancer for patients who are on active surveillance. Active surveillance means that instead of immediate treatment, doctors closely monitor the cancer to see if it changes over time. This trial aims to find out if using MRI scans more often can spot cancer progression better and at a lower cost than the current standard approach defined by NICE, which typically includes regular blood tests and biopsies.

To participate in this trial, you need to be at least 18 years old and have localized prostate cancer that is considered low to medium risk. You should also have already had certain types of MRI scans and biopsies. If you are eligible, you will be randomly assigned to either the group that receives regular MRI scans or the group that follows the current standard care. Throughout the study, you'll continue to be monitored, but it won't be a blind study, meaning both you and your doctors will know which approach you're receiving. This trial is currently recruiting male patients aged 65 to 74, and it offers an opportunity to help improve future care for prostate cancer patients.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Age 18 years or above (no upper limit)
• • Patients with a prostate (either cis-male gender or trans-female gender with no prior androgen deprivation hormone use at all).
• • Diagnostic bi-parametric or multiparametric MRI
• • Diagnostic systematic biopsy +/- targeted biopsy
• • A histological diagnosis of localised prostate cancer
• • Patient chosen active surveillance
• Exclusion Criteria:
• • On active surveillance for greater than 9 months prior to screening date.
• • Contraindication to MRI or gadolinium contrast
• • Previous hip replacement to both hips
• • Contraindication to performing a biopsy guided by a transrectal ultrasound probe